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Abstract
Introduction: The occurrence of granulomatous disease in the setting of Hodgkin’s disease is rare; however, when
it occurs it can pose significant clinical and diagnostic challenges for physicians treating these patients.
Case presentation: We report the case of a 33-year-old Caucasian woman of Mediterranean descent with newly
diagnosed
18F-fluorodeoxyglucose (
18F-FDG) positron emission tomography (PET)/computed tomography (CT) scan-
positive, early-stage Hodgkin’s disease involving the cervical nodes who, despite having an excellent clinical
response to chemotherapy, had a persistent
18F-FDG PET scan-positive study, which was suggestive of residual or
progressive disease. A subsequent biopsy of her post-chemotherapy PET-positive nodes demonstrated sarcoidosis
with no evidence of Hodgkin’s disease.
Conclusion: This case highlights the fact that abnormalities observed on posttherapy PET/CT scans in patients with
Hodgkin’s disease are not always due to residual or progressive disease. An association between Hodgkin’s disease
and/or its treatment with an increased incidence of granulomatous disease appears to exist. Certain patterns of
18F-FDG uptake observed on PET/CT scans may suggest other pathologies, such as granulomatous inflammation,
and because of the significant differences in prognosis and management, clinicians should maintain a low
threshold of confidence for basing their diagnosis on histopathological evaluations when PET/CT results appear to
be incongruent with the patient’s clinical response.
Introduction
The use of positron emission tomography (PET)/com-
puted tomography (CT) to evaluate lymphoma, includ-
ing Hodgkin’s disease, continues to increase worldwide
and is considered the standard of care when available
for pretreatment staging and assessment of treatment
response.
PET has been demonstrated to modify disease stage
(usually upstage) in about 15% to 20% of patients and
affect therapeutic management in about 5% to 15% of
patients [1]. PET is considered significantly more accu-
rate than CT for the assessment of treatment response
because of its ability to distinguish between metabolically
active tumor or fibrosis in posttherapy residual masses,
which are present in approximately two-thirds of patients
with Hodgkin’s disease.
Although PET/CT is a highly sensitive technique for
detecting Hodgkin’s disease, other conditions, such as
infection, inflammation and granulomatous disease, may
result in a false-positive scan. An increased incidence of
granulomatous disease has been associated with Hodgkin’s
disease and/or its treatment [2-4]; hence a positive post-
therapy PET/CT scan needs to be interpreted with cau-
tion, particularly if it is incongruent with the patient’s
clinical response.
Here we present the case of a patient with residual
PET scan positivity following seemingly successful treat-
ment of early-stage Hodgkin’s disease which subse-
quently was confirmed to be due to granulomatous
disease.
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A 33-year-old, previously well Caucasian woman of Med-
iterranean descent presented to our hospital with asymp-
tomatic left cervical lymphadenopathy for further
investigation. There were no associated symptoms of
night sweats, weight loss or fever. A subsequent exci-
sional biopsy of a left supraclavicular node demonstrated
features consistent with classical nodular sclerosing
Hodgkin’s lymphoma, with nodular aggregates of small
lymphocytes interspersed with CD30+ and CD15+ lacu-




PET/CT scan was confounded by prominent physiologi-
cal brown fat uptake in the neck and thorax, but con-
firmed
18F-FDG-avid lymphadenopathy in the left lower
cervical and left supraclavicular regions with no evidence
o fd i s e a s ee l s e w h e r ei nt h eb o d y( P E Ts c a n - c o n f i r m e d
stage IIA Hodgkin’s lymphoma) (Figure 2). Her bone
marrow biopsy was negative for bone marrow involve-
ment. She was subsequently treated with two cycles of
ABVD (doxorubicin, bleomycin, vinblastine and dacarba-
zine) chemotherapy followed by involved field radiother-
apy (30gy delivered in 17 fractions to the left upper chest
and neck).
Ap o s t t h e r a p yr e s t a g i n g
18F-FDG PET/CT scan was
performed two months following the completion of
radiotherapy. The scan demonstrated complete resolu-
tion of
18F-FDG-avid lymphadenopathy in the left cervi-
cal and supraclavicular regions, but new widespread
18F-
FDG-avid bilateral pulmonary hilar and mediastinal lym-
phadenopathy, raising the possibility of progressive
Hodgkin’s disease (Figure 3). A mediastinoscopy was
performed, and several mediastinal nodes were obtained
for histopathological evaluation. These specimens
demonstrated non-necrotizing granulomatous inflamma-
tion with numerous multinucleated giant cells, consis-
tent with sarcoidosis (Fig u r e4 ) .N oe v i d e n c eo f
malignancy was detected, and staining for infective
organisms was negative.
Subsequent investigations, including serum and urin-
ary calcium levels and an ophthalmological review for
ocular sarcoidosis, were normal. Her pulmonary func-
tion tests demonstrated a mild decrease in gas transfer
(62% of predicted value) which was nonspecific and pos-
sibly related to prior radiotherapy. Her chest X-ray was
normal. Cardiac magnetic resonance imaging was per-
formed to evaluate a left anterior hemiblock pattern
visualized on her electrocardiogram, which was negative
for cardiac sarcoidosis. A nonsteroidal anti-inflammatory
drug regimen was commenced for mild chest discomfort
thought to be related to mediastinal lymphadenopathy,
with good relief of symptoms. A course of corticoster-
oids was deemed unnecessary upon a respiratory physi-
cian’s review, and the proposed management plan was
one of close observation.
Discussion
An association between sarcoidosis and Hodgkin’sl y m -
phoma has been raised previously in the literature,
including several case reports and case series describing
sarcoidosis preceding or occurring concurrently with
Hodgkin’s lymphoma [4,5]. An association of sarcoidosis
and lymphoma has also been described by Brincker,
who found that patients with sarcoidosis have a five and
one-half times higher incidence of developing lymphoma
associated with their sarcoidosis [2]. Sporadic case
reports have described sarcoidosis following treatment
of Hodgkin’s lymphoma [3,6,7].
Figure 1 Biopsies confirming nodular sclerosing Hodgkin’s lymphoma with aggregates of small lymphocytes interspersed with CD30+
Reed-Sternberg cells. (A) Hematoxylin and eosin stain; original magnification, × 400. (B) CD30+ cells. Original magnification, × 400.
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18F-fluorodeoxyglucose (
18F-FDG) positron emission tomography/computed tomography scan. (A) Prominent
physiological brown fat uptake in the neck and thorax. (B and C)
18F-FDG-avid lymphadenopathy in the left lower cervical nodes. (D and E)
18F-FDG-avid lymphadenopathy in the left supraclavicular regions.
Figure 3 Posttreatment
18F-fluorodeoxyglucose (
18F-FDG) positron emission tomography/computed tomography scan showing
resolution of
18F-FDG-avid lymphadenopathy in the left cervical and supraclavicular nodes but new bilateral
18F-FDG-avid pulmonary
hilar and mediastinal lymphadenopathy.
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unknown cause that typically affects young to middle-
aged adults and causes non-necrotizing granulomas
composed of epithelioid histocytes which replace the
normal lymph node architecture and at times also infil-
trate body organs such as the lungs. The prevalence of
sarcoidosis is estimated to be between 10 to 20 per
100,000 population; however, the prevalence is not
known with certainty and can vary greatly between geo-
graphical regions. Sarcoidosis is three to four times
more common among African-Americans, who have a
lifetime risk of 2.4% compared to a 0.85% risk among
the Caucasian population in North America [8,9].
Interestingly, sarcoidosis and Hodgkin’s disease appear
to have many immunological features in common, such
as cutaneous anergy, peripheral lymphopenia and promi-
nent infiltration of helper T cells at sites of involvement.
It is possible that a similar underlying dysregulation in
immune function or an immunosuppressive state predis-
poses individuals to both conditions.
Among the other hypotheses that have been postulated
is that Hodgkin’s disease itself or its treatment may con-
tribute to the development of sarcoidosis through immu-
nosuppression or other mechanisms, such as an
idiosyncratic drug reaction. ABVD therapy is a com-
monly utilized regimen for the treatment of Hodgkin’s
disease. Bleomycin differs pharmacokinetically from
other drugs in ABVD combination therapy and has a
relatively higher tissue concentration in the skin, lungs,
kidneys, peritoneum and lymphatics relative to hemato-
poietic tissues [6]. Interestingly, sarcoidosis has a predi-
lection for similar organs; hence a relationship between
the two has been raised [6].
18F-FDG PET/CT is considered the standard tool for
primary staging and assessment of treatment response
in patients with Hodgkin’s lymphoma because of its
high overall sensitivity (> 95%) and specificity (> 90%
pretreatment and 70% to 80% posttreatment) for detect-
ing lymphoma [10-12]. False-positive results do occur,
however, particularly following treatment (in up to 10%
to 40% of cases) [12,13], as a result of other concomi-
tant conditions, such as infection, inflammation and
granulomatous disease, all of which have the potential
to cause increased
18F-FDG uptake during PET.
18F-FDG PET has been demonstrated to have high sen-
sitivity (78% to 95%) for detecting granulomatous
changes and inflammation, with evidence in the literature
confirming its utility as a noninvasive means of monitor-
ing treatment response in patients with sarcoidosis. In
many centers,
18F-FDG PET has surpassed the tradition-
ally used gallium-67 scan for the diagnosis and manage-
ment of patients with sarcoidosis because of its higher
sensitivity for detecting active sites of disease [14].
It is likely that an increasing number of cases of sar-
coidosis will be detected in association with Hodgkin’s
lymphoma or its treatment because of the increasing
use of
18F-FDG PET as the main imaging modality to
stage and assess the progress of this disease. Although
biopsy and histopathological evaluation comprise the
only definitive technique to confirm granulomatous dis-
ease and exclude residual or recurrent lymphoma, clini-
cal features and certain patterns of
18F-FDG uptake on
PET scans often suggest an alternate diagnosis, such as
granulomatous disease.
Bilateral pulmonary hilar and mediastinal nodal
18F-
FDG uptake particularly, if n o ti na no r i g i n a ls i t eo f
Figure 4 Mediastinal nodal sampling showing non-necrotizing granulomatous inflammation with numerous multinucleated giant cells
consistent with sarcoidosis. (A) Hematoxylin and eosin stain; original magnification, × 100. (B) Hematoxylin and eosin stain; original
magnification, × 400.
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possibility of an alternate pathology to Hodgkin’sl y m -
phoma following chemotherapy. This is even more true
in patients with early-stage Hodgkin’s lymphoma, such
as in the present case, in which the prognosis would be
expected to be excellent and relapse or progressive dis-
ease following first-line chemotherapy would be consid-
ered unusual. Symmetry is an important diagnostic
feature of metabolically active pulmonary hilar and med-
iastinal lymphadenopathy associated with sarcoidosis,
which often differentiates it from alternate pathologies,
such as lymphoma, on PET scans [15].
T h el u n g sa r et h em o s tc o m m o ne x t r a n o d a ls i t eo f
involvement with sarcoidosis, and changes can often be
seen on CT scans, particularly if CT is performed at high
resolution [16]. Small, 1 mm to 5 mm pulmonary nodules
with irregular borders predominantly found in the upper
and middle lung zone are the most common and almost
universal finding where there is pulmonary involvement
[17]. The presence of architectural distortion associated
with these nodules is a key feature of pulmonary sarcoi-
dosis, which helps to differentiate it from lymphoma [18].
Pulmonary fibrosis occurs in 20% to 25% of patients with
pulmonary sarcoidosis [15]; however, this usually takes
years to develop and is not a particularly specific finding
in Hodgkin’s disease patients treated with bleomycin, as
this drug itself is associated with pulmonary fibrosis.
Extrathoracic involvement can also occur with sarcoi-
dosis and warrants consideration in situations in which
the PET/CT findings are incongruent with the patient’s
clinical response. Examples of extrathoracic sites of dis-
ease include any nodal group within the body, skin,
eyes, liver, spleen, muscles, bones and parotid glands.
A p a r tf r o mH o d g k i n ’s disease, granulomatous inflam-
mation has also been associated with other neoplasms,
such as T-cell lymphomas, seminomas of the testis,
renal cell carcinoma and nasopharyngeal carcinoma,
where the presence of granulomas in the tumor par-
enchyma has been attributed to the cytokine milieu of
either the main tumor of other cells comprising the
tumor background [19]. It is therefore of vital impor-
tance to scrutinize granulomas closely on the basis of
histological examinations in the setting of neoplasia to
avoid the underdiagnosis of residual viable malignancy.
Differential diagnoses for granulomatous inflammation
in patients with a history of neoplasia include foreign
body reaction to necrotic tumors, associated systemic ill-
ness such as tuberculosis caused by immunosuppression
or a direct reaction to one of the therapeutic agents
given to the patient [19].
Conclusion
Abnormalities on PET/CT scans in patients treated for
Hodgkin’s disease are not always due to residual or
progressive lymphoma, and clinicians should retain a
high index of suspicion for alternative pathologies
when PET/CT results appear incongruent with the
patient’s clinical presentation or response to therapy.
An association appears to exist between Hodgkin’sd i s -
ease and/or its treatment with an increased incidence
of granulomatous disease. Certain patterns of
18F-FDG
uptake on PET scans may suggest granulomatous dis-
ease rather than lymphoma, and because of the differ-
ences in the prognosis and management of the two
conditions, clinicians should maintain a low threshold
for biopsy and histopathological correlation in these
situations.
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